Printer Friendly

GENSIA LABORATORIES RECEIVES ANDA APPROVAL FOR DOBUTAMINE

 SAN DIEGO, Nov. 1 /PRNewswire/ -- Gensia, Inc. (NASDAQ: GNSA), today announced that Gensia Laboratories, Ltd. (a wholly owned subsidiary of Gensia, Inc.), has received approval of an Abbreviated New Drug Application (ANDA) from the Food and Drug Administration (FDA) to market injectable dobutamine, an acute-care drug used primarily in the treatment of patients with congestive heart failure. With this ANDA approval, Gensia Laboratories now has 24 approved ANDAs covering 19 multi-source (generic) drugs, aAccording to David G. Hale, chairman, president and chief executive officer of Gensia, Inc.
 "We are pleased to gain approval of this important new product, one of the significant products we have targeted as part of our strategy to market acute-care multi-source products in the fields of anti-infectives, cardiology, anesthesiology and oncology," said Hale. "We hope to receive an ANDA approval for an oncology product later this year."
 Gensia Laboratories, Ltd., is located in Irvine, Calif., and develops, manufactures and markets multi-source injectable drug products for the acute-care hospital market.
 Gensia, Inc., is a San Diego-based biopharmaceutical company formed to discover, develop, manufacture and market novel pharmaceutical products for the treatment and diagnosis of human diseases.
 -0- 11/1/93
 /CONTACT: Elizabeth A. Gard of Gensia, 619-546-8300/
 (GNSA)


CO: Gensia, Inc.; Gensia Laboratories, Ltd. ST: California IN: MTC SU:

TW-TA -- NY013 -- 8985 11/01/93 09:02 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 1, 1993
Words:221
Previous Article:EHRENKRANTZ ISSUES 'BUY' RECOMMENDATION ON NETWORK FINANCIAL SERVICES
Next Article:PAUL S. BEIDEMAN NAMED MELLON PSFS PRESIDENT
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters